<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; AstraZeneca plc</title>
	<atom:link href="http://www.stockbloghub.com/tag/astrazeneca-plc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) US Court Rejects AstraZeneca&#8217;s Case</title>
		<link>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196</link>
		<comments>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196#comments</comments>
		<pubDate>Thu, 19 Apr 2012 20:24:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97196</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA). AstraZeneca had taken legal action against the FDA, challenging the agency’s decision to reject AstraZeneca’s Citizen Petitions. The Citizen Petitions were filed by the company for Seroquel (quetiapine fumarate) and Seroquel XR. The Citizen Petitions were filed to bar the FDA from approving any generic versions of the drug that do not include warnings related to hyperglycemia and suicidality in its label. With this move, AstraZeneca was looking to delay the launch of generic versions of Seroquel considering the company has marketing exclusivity for the data associated with the hyperglycemia warning till December 2, 2012. Meanwhile, the UK High Court has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Inks Deal with Cephalon</title>
		<link>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439</link>
		<comments>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:53:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97439</guid>
		<description><![CDATA[The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA).  Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study. Over the recent past, the company has entered into similar agreements with players such as Abbott (ABT), Astra Zeneca (AZN) and BioMarin Pharmaceuticals (BMRN) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad’s flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman&#8217;s risk for hereditary breast and ovarian cancer. Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis&#8217; Cancer Drug Afinitor Shows Promise for Breast Cancer</title>
		<link>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414</link>
		<comments>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414#comments</comments>
		<pubDate>Mon, 12 Dec 2011 22:12:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Tenaris SA]]></category>
		<category><![CDATA[TS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88414</guid>
		<description><![CDATA[Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an indication for which management estimates sales potential in excess of $1 billion. Afinitor is not yet approved for the treatment of breast cancer. The pivotal late-stage study (BOLERO-2) evaluated the use of Afinitor in combination with Pfizer’s (PFE) Aromasin (a hormonal therapy) in postmenopausal women with metastatic breast cancer whose disease has progressed, despite treatment with hormonal therapies like Novartis’ Femara or AstraZeneca’s (AZN) Arimidex. The long-term data showed that Afinitor plus Aromasin expanded progression-free survival (PFS), or time, without causing tumor growth in patients, by more than two times versus Aromasin alone. Treatment with Afinitor improved the PFS to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/12/nvs-novartis-cancer-drug-afinitor-shows-promise-for-breast-cancer/88414/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278</link>
		<comments>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278#comments</comments>
		<pubDate>Fri, 09 Dec 2011 17:40:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88278</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also adjusting for the change in fair value of warrants). Lower-than-expected revenues led to the wider loss in the quarter. Revenues at Micromet were down almost 33% from the prior-year period to $4.5 million in the third quarter of 2011 due to lower collaboration revenue. Moreover, revenues in the year-ago quarter were boosted by the presence of a milestone payment from AstraZeneca (AZN). Revenues were also much below the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Drug Cleared by the European Commission</title>
		<link>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920</link>
		<comments>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920#comments</comments>
		<pubDate>Thu, 08 Dec 2011 19:01:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87920</guid>
		<description><![CDATA[AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for type II diabetes. AstraZeneca has co-developed Onglyza with Bristol-Myers. The EC cleared Komboglyze as an adjunct to diet and exercise to improve glycemic control in adults suffering from type II diabetes. Komboglyze is indicated for patients who show inadequate response to the maximum tolerated dose of metformin alone or those already being treated with the combination of Onglyza and metformin as separate tablets. Komboglyze is expected to provide single pill dosing convenience to patients currently taking Onglyza and metformin seperately. We remind investors that Komboglyze was approved by the US ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960</link>
		<comments>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960#comments</comments>
		<pubDate>Sat, 24 Sep 2011 18:58:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83960</guid>
		<description><![CDATA[Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for the District of Massachusetts. The lawsuit claims that Amphastar Pharma&#8217;s generic Lovenox, which was approved by the US Food and Administration (FDA) on September 19, infringes two of Momenta&#8217;s US patents. Amphastar Pharma plans to launch generic Lovenox in the US in the fourth quarter of 2011. Lovenox is indicated for the prophylaxis and treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction. According to IMS Health, US sales of Lovenox and its generic equivalents amounted to about $2.6 billion for the twelve months ended ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692</link>
		<comments>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692#comments</comments>
		<pubDate>Wed, 21 Sep 2011 14:56:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83692</guid>
		<description><![CDATA[We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include: gastrointestinal, cardiovascular, respiratory and inflammation, oncology, neuroscience, infection and other. The company’s key products include Crestor (cholesterol management); Nexium (acid reflux); Seroquel (schizophrenia and bipolar mania); Atacand (hypertension and symptomatic heart failure), Arimidex (breast cancer), Zoladex (prostate and breast cancer) and Symbicort (asthma). We are impressed by the performance of lead drug Crestor which is primarily responsible for AstraZeneca being one of the leading players in the global cardiovascular market. The US launch of Brilinta (ticagrelor) for the reduction of the rate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Now in US</title>
		<link>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949</link>
		<comments>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81949</guid>
		<description><![CDATA[AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following the launch, AstraZeneca plans to work with distribution partners and pharmacy customers to ensure that Brilinta is readily available for use. The regulatory body’s approval was based on the PLATO study, which compared Brilinta to clopidogrel in 18,624 patients suffering from ACS. The study demonstrated that there was no statistical difference in adverse reactions observed among patients treated with Brilinta, compared to those treated with clopidogrel. Clopidogrel, which is marketed worldwide by Bristol-Myers Squibb &#38; Co. (BMY) and Sanofi-Aventis (SNY) under the brand name Plavix, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145</link>
		<comments>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:26:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82145</guid>
		<description><![CDATA[We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks Consensus Estimate by a penny and the year-ago earnings by 18 cents. Earnings were bolstered by higher revenues. Revenues for the quarter climbed 24% to $1.08 billion, beating the Zacks Consensus Estimate of $992 million. Revenues went up mainly due to increased generic and branded drug sales. Following the better-than-expected second quarter results, Watson Pharma increased its 2011 earning guidance range to $4.25-$4.50 per share from $3.95-$4.20. We note that the company enjoys a strong position in the generic pharmaceutical market. At the end of 2010, Watson Pharma had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823</link>
		<comments>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823#comments</comments>
		<pubDate>Thu, 25 Aug 2011 16:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81823</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents and also beat the year-ago earnings 37 cents. Earnings growth was driven by an increase in generics revenue and improved gross margins. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 17% to $1.44 billion in the second quarter of 2011 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in other markets like Asia-Pacific and North America. Mylan is one of the leading players in the generics market. A large number of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Reports Solid Quarter</title>
		<link>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:53:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80092</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the quarter decreased 2% to $0.52 per share. The healthcare reform enacted in 2010 negatively impacted earnings in the reported quarter by $0.03. Net sales in the reported quarter climbed 14% to $5.4 billion. Foreign exchange positively impacted sales in the quarter by 4%. Revenues also surpassed the Zacks Consensus Estimate of $5.0 billion, driven by the impressive showing of Bristol-Myers’ lead drugs including blood thinner Plavix. US net sales in the quarter climbed 15% to $3.6 billion. Sales in international markets increased 13% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds</title>
		<link>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075</link>
		<comments>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:43:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AHS]]></category>
		<category><![CDATA[AMN Healthcare Services Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Total System Services Inc]]></category>
		<category><![CDATA[TSS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79075</guid>
		<description><![CDATA[Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic&#8217;s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership, Apax exclusively focuses on long-term investment in growth companies. The acquisition of Kinetic is part of Apax’s intention to support deals in the financial &#38; business services, healthcare, media, retail &#38; consumer and technology sectors. However, probably its budget doesn’t permit such a big acquisition at this point, so Apax teamed up with the Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments) to get the deal done. As per the terms of the agreement, Kinetic’s shareholders will receive $68.50 in cash for each share of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/07/06/miti-micromet-analyst-maintains-neutral-on-shares/78499</link>
		<comments>http://www.stockbloghub.com/2011/07/06/miti-micromet-analyst-maintains-neutral-on-shares/78499#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:17:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78499</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $6.00 per share. We believe Micromet’s lead pipeline candidate, blinatumomab, holds tremendous potential in the treatment of Acute lymphoblastic leukemia (ALL). Blinatumomub is one of the leading BiTE antibodies. BiTE antibodies represent a new class of antibodies that activate the T-cells of a patient’s immune system to eliminate cancer cells. The company is conducting a pivotal study of blinatumomab (MT103) in Europe in adults with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL), also referred to as front-line ALL. The company also has a mid-stage study (n=20) of blinatumomab underway in adults suffering from relapsed or refractory B-precursor ALL. Micromet has presented encouraging data from both trials. We believe the successful development and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/miti-micromet-analyst-maintains-neutral-on-shares/78499/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Restructures Branded Business</title>
		<link>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319</link>
		<comments>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:22:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78319</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) is in for a strategic assessment as it announced restructuring plans for its branded drugs segment, Strativa Pharmaceuticals. The company will reduce its workforce by about 100 people as a result of the restructuring, which is expected to drive the Strativa business to profitability. The workforce reduction will help Par Pharma focus on its products, Megace ES and Nascobal. Consequently, in the second quarter of 2011, Par Pharma will incur one-time non-cash charges along with severance costs. The restructuring initiative is expected to generate operating expense savings of $8-$12 million for the rest of 2011. The company believes this initiative will boost Strativa to profitability in the near term. We expect the restructuring program to benefit the company, which witnessed a 20.9% drop in revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154</link>
		<comments>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78154</guid>
		<description><![CDATA[Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion into Europe. With respect to new products, Myriad aims to launch at least one new molecular diagnostic product each year. The company’s tenth product, slated for launch in the second half of 2011, will assist dermatopathologists in determining whether a patient’s mole is benign or a malignant melanoma. We are also encouraged by Myriad’s recent acquisition of Texas based, privately-held Rules-Based Medicine (RBM) for $80 million in cash. This deal would expand the company’s portfolio to take into its ambit psychiatric disorders, infectious diseases and inflammatory diseases. According to Myriad, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies</title>
		<link>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:34:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77782</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated their type II diabetes candidate dapagliflozin in conjunction with the extended-release version of metformin (XR). Data from the two 24-week studies, which evaluated adults suffering from type II diabetes, were presented at the American Diabetes Association (ADA) Scientific Sessions. Data from the studies revealed that there was a significant reduction in blood sugar levels in patients treated with dapagliflozin and metformin XR versus those treated with dapagliflozin or metformin XR alone and placebo. Moreover, no major events related to hypoglycemia were reported in the studies. Hypoglycemia refers to the situation of abnormally low levels of glucose in the blood. Results also revealed that patients treated with the combination of dapagliflozin and metformin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Ties Up with Pharma Majors</title>
		<link>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570</link>
		<comments>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[Neuberger Berman High Yield Strategies Fund]]></category>
		<category><![CDATA[NGS]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77570</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently strengthened its newly created Technology Strategy Board grant consortium with the inclusion of the R&#38;D divisions of AstraZeneca (AZN) and Johnson &#38; Johnson (JNJ). The group expects this grant to fund the development of a commercial multi-gene next generation sequencing test, which will provide comprehensive molecular profiles of tumors and identify treatment options. Life Technologies believes that the test will increase the speed and accuracy of cancer treatment. With the application of the next generation sequencing (NGS) and informatics, this genomic test will be commercially available in the global market. This program will attract additional pharmaceutical clinical trial investments in UK that should prove to be a major source of international investment. Thus, the consortium expects this new program to add life to the economic condition ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRAY) DENTSPLY Grabs Astra Tech for $1.8 Billion</title>
		<link>http://www.stockbloghub.com/2011/06/23/xray-dentsply-grabs-astra-tech-for-1-8-billion/77293</link>
		<comments>http://www.stockbloghub.com/2011/06/23/xray-dentsply-grabs-astra-tech-for-1-8-billion/77293#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:03:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77293</guid>
		<description><![CDATA[In a bid to bolster its foothold in the global dental market, leading dental products maker DENTSPLY International (XRAY) has agreed to buy Astra Tech, the dental implant division of multinational drug major AstraZeneca PLC (AZN), for $1.8 billion in cash. The Anglo-Swiss pharmaceutical giant is selling the dental unit to renew focus on its core prescription drug business. Other financial terms of the deal were not disclosed by the entities. The transaction, which is subject to antitrust clearance, is expected to complete by end-2011. Morgan Stanley (MS) is acting as financial advisor to DENTSPLY on the deal. DENTSPLY plans to finance the acquisition with cash, commercial paper and long-term debt. The company had cash and cash equivalents of roughly $575.3 million in first-quarter fiscal 2011. Compelling Prospect Sweden-based Astra ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/xray-dentsply-grabs-astra-tech-for-1-8-billion/77293/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(APOG) Company News for June 23, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238</link>
		<comments>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238#comments</comments>
		<pubDate>Thu, 23 Jun 2011 16:06:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[General Building Materials]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[APOG]]></category>
		<category><![CDATA[Apogee Enterprises Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FDX]]></category>
		<category><![CDATA[FedEx Corporation]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Jabil Circuit Inc.]]></category>
		<category><![CDATA[JBL]]></category>
		<category><![CDATA[RBN]]></category>
		<category><![CDATA[Robbins & Myers Inc]]></category>
		<category><![CDATA[SCBT]]></category>
		<category><![CDATA[SCBT Financial Corporation]]></category>
		<category><![CDATA[Western Refining Inc.]]></category>
		<category><![CDATA[WNR]]></category>
		<category><![CDATA[XRAY]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77238</guid>
		<description><![CDATA[•    Shares of Robbins &#38; Myers, Inc. (NYSE:RBN) jumped 8.77% on strong fiscal third-quarter profits. The energy equipment supplier said strong customer demand and the recent acquisition of oilfield services has helped the company&#8217;s increase its profits •    Shares of Jabil Circuit (NYSE:JBL) gained 3.18% to close at $19.45 after the company posted earnings that doubled from the previous year. The company also initiated buyback of $200 million of stock •    Apogee Enterprises (NASDAQ:APOG) reported a Q1 loss of $0.08 per share. Revenues increased 7.2% year-over-year to $153.3 million, surpassing the Zacks Consensus Estimate of $147.0 million •    Share prices of shipping service giant FedEx (NYSE:FDX) rose 2.59% after the company posted earnings that came in above analysts’ expectations. The company also projected robust earnings growth for 2012 •    DENTSPLY ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/apog-company-news-for-june-23-2011-corporate-summary/77238/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap</title>
		<link>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633</link>
		<comments>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:42:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76633</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded in getting the drug approved in the US for the indication in its second attempt. In the second quarter of 2010, the FDA issued a complete response letter in response to biologic license application (BLA) submitted by the pharma major for Nulojix , asking for additional information. Subsequently, Bristol-Myers submitted it. In December 2010, the agency had thereby announced that it would review the re-submitted application by June 15, 2011 (action date). The agency cleared the drug following the review thereby delivering a further boost to the company. We note that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) Roche Holdings&#8217; Skin Cancer Drug Impresses</title>
		<link>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908</link>
		<comments>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908#comments</comments>
		<pubDate>Sun, 12 Jun 2011 17:14:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75908</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO). The BRIM 3 study was conducted to compare vemurafenib with dacarbazine (chemotherapy) in patients with previously untreated BRAF V600 mutation-positive, unresected, locally advanced or metastatic melanoma (skin cancer). Upon comparison with chemotherapy, the study results demonstrated that patients on vemurafenib experienced a significant improvement in overall survival, with the risk of death reducing by 63%. The study also met the co-primary endpoint of reducing the risk of disease aggravation by 74% compared with chemotherapy. Last month, Roche submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AFFX) Company News for June 03, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/03/affx-company-news-for-june-03-2011-corporate-summary/75495</link>
		<comments>http://www.stockbloghub.com/2011/06/03/affx-company-news-for-june-03-2011-corporate-summary/75495#comments</comments>
		<pubDate>Sat, 04 Jun 2011 05:03:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Scientific & Technical Instruments]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[EnergySolutions Inc]]></category>
		<category><![CDATA[ES]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Joy Global Inc.]]></category>
		<category><![CDATA[JOYG]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sempra Energy]]></category>
		<category><![CDATA[SRE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75495</guid>
		<description><![CDATA[•    Joy Global Inc. (NASDAQ:JOYG) posted Q2 EPS of $1.52, higher than the Zacks Consensus Estimate of $1.35 per share. Revenue for the quarter grew 19% to $1.06 billion, beating the Zacks Consensus Estimate of $1.038 billion •    According to reports, Ford Motor Co (NYSE:F) is planning to invest around $100 million in robotic laser technology which will reduce wind noise inside vehicles •    Baird upgraded shares of Affymetrix, Inc. (NASDAQ:AFFX) to &#8220;Outperform&#8221; rating from &#8220;Neutral&#8221; rating, raising the target price to $11 from $6 •    Shares of Johnson &#38; Johnson (NYSE:JNJ) were upgraded by analysts of First Global to &#8220;Moderate Outperform&#8221; rating from &#8220;Market Perform&#8221; rating •    Analysts at BofA Merrill Lynch upgraded DeVry Inc. (NYSE:DV) to &#8220;Buy&#8221; rating from &#8220;Neutral&#8221; rating with a target price of $68 on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/03/affx-company-news-for-june-03-2011-corporate-summary/75495/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Revenues Fall &#8211; Outlook Improves</title>
		<link>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038</link>
		<comments>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73038</guid>
		<description><![CDATA[AstraZeneca plc (AZN) reported first-quarter fiscal 2011 core earnings of $2.23 per American Depositary Share (ADS), reflecting an increase of 10% (at constant exchange rates [CER]) from the prior-year quarter. The Zacks Consensus Estimate for the reported quarter was $2.04 per share. Including one-time items, earnings came in at $2.08, up 10%. Despite lower revenues, earnings climbed as a result of lower tax rate and lower number of shares outstanding. Revenues AstraZeneca’s first quarter revenues declined 4% year over year to $8.3 billion owing to intense generic competition and government price interventions. However, revenues were in line with the Zacks Consensus Estimate. Generic competition for major products in the US and the impact of the healthcare reform led to an 11% slide in US revenues. The Rest of the World ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs First Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667</link>
		<comments>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667#comments</comments>
		<pubDate>Mon, 18 Apr 2011 14:31:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71667</guid>
		<description><![CDATA[Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average of 1.0%. Fourth Quarter 2010 Recap Abbott Laboratories reported fourth quarter earnings of $1.30 per share, a penny above the Zacks Consensus Estimate. Earnings increased 10.2% from the year-ago period. Higher revenues helped drive results. However, including one-time items, earnings declined 6.1% to $0.92 per share. Fourth quarter revenues increased 13.4% to $9.97 billion, above the Zacks Consensus Estimate of $9.89 billion. (Read our full coverage on the earnings report at Abbott Labs Tops ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Learns Medicare May Pay for Provenge Prostate Cancer Vaccine</title>
		<link>http://www.stockbloghub.com/2011/04/10/dndn-dendreon-learns-medicare-may-pay-for-provenge-prostate-cancer-vaccine/70376</link>
		<comments>http://www.stockbloghub.com/2011/04/10/dndn-dendreon-learns-medicare-may-pay-for-provenge-prostate-cancer-vaccine/70376#comments</comments>
		<pubDate>Mon, 11 Apr 2011 02:58:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70376</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) received a huge boost today when the Centers for Medicare and Medicaid Services (CMS) proposed to pay for its lead prostate cancer vaccine Provenge. Provenge was approved in the US in April last year and is marketed since May 2010. It is currently reimbursed by all 15 local Medicare contractors. CMS issued the proposed decision memo for Dendreon’s potential blockbuster vaccine, Provenge, after conducting a scientific review of the evidence provided. The agency believes there is enough evidence to justify reimbursement for the approved label of the vaccine. CMS believes Provenge leads to improvement in health outcomes for men with advanced, castrate-resistant prostate cancer (CRPC) and is clinically necessary, as per CMS. The agency did not propose to cover off-label use of the vaccine at the national ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/dndn-dendreon-learns-medicare-may-pay-for-provenge-prostate-cancer-vaccine/70376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Drug Vandetanib Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/04/09/azn-astrazeneca-drug-vandetanib-earns-fda-approval/70911</link>
		<comments>http://www.stockbloghub.com/2011/04/09/azn-astrazeneca-drug-vandetanib-earns-fda-approval/70911#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:21:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70911</guid>
		<description><![CDATA[AstraZeneca (AZN) recently gained US Food and Drug Administration (FDA) approval for its orphan drug vandetanib for the treatment of non-operable (unresectable) locally advanced or metastatic medullary thyroid cancer (MTC). The approval, however, comes with a boxed warning and a Risk Evaluation and Mitigation Strategy (REMS). The boxed warning relates to QT prolongation, Torsades de pointes, and sudden death. Vandetanib’s approval was based on encouraging phase III data which showed that treatment with vandetanib resulted in a 65% reduction in the rate of disease progression compared to placebo. In addition to achieving the primary endpoint of progression-free survival, vandetanib also showed improvement compared to placebo in the secondary endpoints, which were objective response rate and disease control rate. The randomized, double-blind, placebo-controlled, multi-center study ZETA was conducted with 331 patients ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/azn-astrazeneca-drug-vandetanib-earns-fda-approval/70911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing</title>
		<link>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983</link>
		<comments>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:13:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70983</guid>
		<description><![CDATA[Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total revenue. This test provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing woman&#8217;s risk of hereditary breast and ovarian cancers. Under the agreement, the company will carry out Bracanalysis test to identify the presence of germline mutations in the patients prior to enrollment in the study. Accordingly, it will provide standard test reports to the clinicians. Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/01/dndn-dendreon-analyst-maintains-neutral-rating-on-shares/70480</link>
		<comments>http://www.stockbloghub.com/2011/04/01/dndn-dendreon-analyst-maintains-neutral-rating-on-shares/70480#comments</comments>
		<pubDate>Fri, 01 Apr 2011 16:17:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Nidec Corporation]]></category>
		<category><![CDATA[NJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70480</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $39.00 following the announcement of fourth quarter and full year 2010 financial results. Dendreon’s fourth quarter 2010 loss of 61 cents per share (excluding loss on debt conversion) was wider than the Zacks Consensus Estimate of a loss of 48 cents per share and the year-ago loss of 31 cents per share (excluding gain for warrant revaluation). On a reported basis (including special items), the company lost 64 cents per share in the fourth quarter as against a loss of 28 cents per share in the year-ago quarter. The wider loss was attributable to higher operating expenses as the company is working on expanding its facilities to market Provenge. Dendreon’s lead product is prostate cancer ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/01/dndn-dendreon-analyst-maintains-neutral-rating-on-shares/70480/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Ramps Up Earnings &#8211; Settles Disputes</title>
		<link>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805</link>
		<comments>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:02:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67805</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents. For full year 2010, PDL reported earnings per share of 97 cents, down from $1.06 per share in 2009 but ahead of the Zacks Consensus Estimate of 90 cents. Full year 2010 revenues of $345 million were well above the prior-year figure of $318.2 million. Revenues also beat the Zacks Consensus Estimate of $343 million. 2009 revenues included royalties from MedImmune, a subsidiary of AstraZeneca (AZN), on sales of Synagis, which PDL no longer receives. Excluding this revenue, sales were up 30% over the prior year. Quarterly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Announces Response to FDA Complete Response Letter</title>
		<link>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664</link>
		<comments>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664#comments</comments>
		<pubDate>Tue, 25 Jan 2011 02:48:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65664</guid>
		<description><![CDATA[AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided additional analyses of the Study of Platelet Inhibition and Patient Outcomes (PLATO) as requested by the FDA. AstraZeneca is looking to get Brilinta approved for the treatment of acute coronary syndrome (ACS). CRL Issued in Dec 2010 The FDA had issued a CRL on Dec 16, 2010 for Brilinta. At that time, the agency had asked AstraZeneca to conduct additional analyses of data from the PLATO trial. The trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). The company said that the additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab</title>
		<link>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405</link>
		<comments>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405#comments</comments>
		<pubDate>Wed, 22 Dec 2010 21:07:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63405</guid>
		<description><![CDATA[AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US Food and Drug Administration (FDA) to withdraw the Biological License Application (BLA) for the candidate. AstraZeneca expects to incur an impairment charge of $445 million in the fourth quarter of 2010 due to the discontinuation of the development of the candidate. The impairment charge, however, is not expected to impact the company’s core earnings. Rough Regulatory Path for Motavizumab AstraZeneca’s decision does not come as a major surprise as the regulatory process for motavizumab has been rocky. Earlier this year, the FDA’s Antiviral Drugs Advisory Committee had voted against the approval of motavizumab for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers FDA Regulatory Setback</title>
		<link>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756</link>
		<comments>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756#comments</comments>
		<pubDate>Sat, 18 Dec 2010 20:54:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62756</guid>
		<description><![CDATA[AstraZeneca (AZN) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for Brilinta (ticagrelor). The company was seeking approval for the use of Brilinta in the treatment of acute coronary syndrome (ACS). The agency has asked AstraZeneca to conduct additional analyses of data from the Study of Platelet Inhibition and Patient Outcomes (PLATO). The PLATO trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). Importantly, AstraZeneca has not been asked to conduct additional studies which could have delayed the approval process even further. The additional delay in Brilinta’s approval is a big disappointment for AstraZeneca which has been banking on Brilinta&#8217;s approval to help ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACN) Company News for December 17, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/12/17/acn-company-news-for-december-17-2010-corporate-summary/62639</link>
		<comments>http://www.stockbloghub.com/2010/12/17/acn-company-news-for-december-17-2010-corporate-summary/62639#comments</comments>
		<pubDate>Fri, 17 Dec 2010 23:10:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Management Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Accenture Limited]]></category>
		<category><![CDATA[ACN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Oracle Corporation]]></category>
		<category><![CDATA[ORCL]]></category>
		<category><![CDATA[Research In Motion Limited]]></category>
		<category><![CDATA[RIMM]]></category>
		<category><![CDATA[Take-Two Interactive Software Inc]]></category>
		<category><![CDATA[TTWO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62639</guid>
		<description><![CDATA[• Oracle (NASDAQ:ORCL) reported fiscal second quarter earnings of $0.51, beating the Zacks Consensus Estimate of $0.44, on revenues of $8.6 billion that topped the Zacks Consensus Estimate of $8.3 billion • Take-Two Interactive Software (NASDAQ:TTWO) posted stronger fiscal fourth quarter earnings of $0.67 ahead the Zacks Consensus Estimate of $0.23, revenues up 32% to $374 million, ahead of Zacks Consensus Estimate of$ 223 million. • Research In Motion&#8217;s (NASDAQ:RIMM) posted third quarter earnings of $1.74 ahead of the Zacks Consensus Estimate of $1.64, as revenues increased by 19% to $5.5 billion, ahead of the Zacks Consensus Estimate of  $5.49 billion • Accenture&#8217;s (NYSE:ACN) reported fiscal first quarter earnings of $0.81 ahead of the Zacks Consensus Estimate of $0.75, as revenues increased by 32% to $6.1 billion, ahead of the Zacks Consensus Estimate of  ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/17/acn-company-news-for-december-17-2010-corporate-summary/62639/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Beats Expectations on EPS &#8211; Misses on Sales</title>
		<link>http://www.stockbloghub.com/2010/11/07/bmy-bristol-myers-squibb-beats-expectations-on-eps-misses-on-sales/56688</link>
		<comments>http://www.stockbloghub.com/2010/11/07/bmy-bristol-myers-squibb-beats-expectations-on-eps-misses-on-sales/56688#comments</comments>
		<pubDate>Sun, 07 Nov 2010 20:29:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Enterprises Inc.]]></category>
		<category><![CDATA[CHB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56688</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) third quarter 2010 earnings (excluding special items) of $0.59 per share surpassed the Zacks Consensus Estimate by $0.06. The company had earned $0.47 per share in the year-ago quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the reported quarter climbed 22% to $0.55 per share. Even though Bristol-Myers’ lead product Plavix and therapies indicated for HIV and hepatitis performed well in the quarter, the better than expected earnings were mainly driven by cost controls and lower taxes. Net sales in the reported quarter came in flat at $4.8 billion. Revenues were short of the Zacks Consensus revenue Estimate of $4.9 billion mainly because of lower sales of Abilify, approved for the treatment of schizophrenia and depression, cancer drug Erbitux and hypertension treatment Avapro. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/07/bmy-bristol-myers-squibb-beats-expectations-on-eps-misses-on-sales/56688/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(REGN) Regeneron Pharmaceuticals Quarterly Loss Wider than Expected</title>
		<link>http://www.stockbloghub.com/2010/11/07/regn-regeneron-pharmaceuticals-quarterly-loss-wider-than-expected/58000</link>
		<comments>http://www.stockbloghub.com/2010/11/07/regn-regeneron-pharmaceuticals-quarterly-loss-wider-than-expected/58000#comments</comments>
		<pubDate>Sun, 07 Nov 2010 20:24:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58000</guid>
		<description><![CDATA[Regeneron Pharmaceuticals Inc.&#8216;s (REGN) third quarter 2010 net loss of 41 cents per share was wider than the Zacks Consensus Estimate of a net loss of 34 cents. The company suffered a loss of 1 cent per share in the year-ago quarter. The wider loss was attributable to lower revenues and higher expenses incurred in the reported quarter. Total revenue in the reported quarter declined 9.8% to $106 million. Revenues fell well short of the Zacks Consensus Estimate of $114 million. Total revenues included collaboration revenue, technology licensing revenue, net product sales and contract research and other revenue. The fall in total revenue was mainly attributable to the receipt of a $20 million substantive milestone payment from Bayer HealthCare in the year-ago quarter, partly mitigated by higher revenue in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/07/regn-regeneron-pharmaceuticals-quarterly-loss-wider-than-expected/58000/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb&#8217;s Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/10/15/bmy-bristol-myers-squibbs-pipeline-advances/55259</link>
		<comments>http://www.stockbloghub.com/2010/10/15/bmy-bristol-myers-squibbs-pipeline-advances/55259#comments</comments>
		<pubDate>Fri, 15 Oct 2010 18:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55259</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study (n=814). The patients enrolled in the study, were above 18 years of age and had responded unsatisfactorily to treatment by metformin alone. Dapagliflozin, a once-daily pill, is being co-developed with AstraZeneca Plc (AZN) for treating patients suffering from type II diabetes which is characterized by the dysfunction of beta cells in the pancreas. This results in reduced insulin secretion thereby leading to elevated glucose levels. Results from the 52 week study, presented at the European Association for the Study of Diabetes (EASD), revealed that a combination of dapagliflozin and metformin was as effective as the combination of glipizide and metformin in reducing blood sugar ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/15/bmy-bristol-myers-squibbs-pipeline-advances/55259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Trial Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2010/10/03/bmy-bristol-myers-squibb-trial-presents-encouraging-data/52798</link>
		<comments>http://www.stockbloghub.com/2010/10/03/bmy-bristol-myers-squibb-trial-presents-encouraging-data/52798#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:33:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52798</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study (n=814). The patients enrolled in the study, were more than or equal to 18 years of age and had responded unsatisfactorily to treatment by metformin alone. Dapagliflozin, a once-daily pill, is being co-developed with AstraZeneca Plc (AZN) for treating patients suffering from type II diabetes, which is characterized by the dysfunction of beta cells in the pancreas. This results in reduced insulin secretion, thereby leading to elevated glucose levels. Results from the 52 week study, presented at the European Association for the Study of Diabetes (EASD), revealed that a combination of dapagliflozin and metformin was as effective as the combination of glipizide and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/bmy-bristol-myers-squibb-trial-presents-encouraging-data/52798/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Receives Positive European Union Opinion for Drug</title>
		<link>http://www.stockbloghub.com/2010/09/28/azn-astrazeneca-receives-positive-european-union-opinion-for-drug/52848</link>
		<comments>http://www.stockbloghub.com/2010/09/28/azn-astrazeneca-receives-positive-european-union-opinion-for-drug/52848#comments</comments>
		<pubDate>Tue, 28 Sep 2010 14:09:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52848</guid>
		<description><![CDATA[AstraZeneca (AZN) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Brilique (ticagrelor). The company is seeking approval in the EU for the use of Brilique in the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (ACS). The positive recommendation was based on data submitted by the company on Brilique including data from the PLATO study. A final decision from the European marketing approval authority should be out within a few months. US Decision Expected in December The candidate is currently under regulatory review in twelve regions Incorporatedluding the US, where AstraZeneca intends to market it under the trade name Brilinta. With the US Food and Drug Administration (FDA) recently extending its review period for Brilinta by three months, a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/28/azn-astrazeneca-receives-positive-european-union-opinion-for-drug/52848/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Diabetes Drug Candidate Encourages</title>
		<link>http://www.stockbloghub.com/2010/09/21/bmy-bristol-myers-squibb-company-diabetes-drug-candidate-encourages/52428</link>
		<comments>http://www.stockbloghub.com/2010/09/21/bmy-bristol-myers-squibb-company-diabetes-drug-candidate-encourages/52428#comments</comments>
		<pubDate>Wed, 22 Sep 2010 03:17:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52428</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, international, randomized, parallel-group, double-blind, placebo-controlled study (n=597). Dapagliflozin, a once-daily pill, is being co-developed with AstraZeneca Plc (AZN) for treating patients suffering from type II diabetes which is characterized by the dysfunction of beta cells in the pancreas. This results in reduced insulin secretion thereby leading to elevated glucose levels. Results from the 24 week study, presented at the European Association for the Study of Diabetes (EASD) revealed that a combination of dapagliflozin and glimepiride was more effective in reducing blood sugar levels compared to glimepiride and a placebo. Moreover, the weight reduction was higher in patients treated with the combination of dapagliflozin and glimepiride. Patients receiving dapagliflozin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/21/bmy-bristol-myers-squibb-company-diabetes-drug-candidate-encourages/52428/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Announces Aquisition of Indian Company Piramal Healthcare</title>
		<link>http://www.stockbloghub.com/2010/09/10/abt-abbott-labs-announces-aquisition-of-indian-company-piramal-healthcare/50974</link>
		<comments>http://www.stockbloghub.com/2010/09/10/abt-abbott-labs-announces-aquisition-of-indian-company-piramal-healthcare/50974#comments</comments>
		<pubDate>Fri, 10 Sep 2010 16:04:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50974</guid>
		<description><![CDATA[Abbott Labs (ABT) recently completed its acquisition of Indian company Piramal Healthcare Ltd.’s Healthcare Solutions business (Domestic Formulations) for $3.8 billion. In addition to an upfront payment of $2.2 billion, Abbott Labs will pay $400 million annually over the next 4 years. Position Strengthened in Indian Pharma Market The acquisition of Piramal’s Healthcare Solutions business should catapult Abbott Labs to the top position in the Indian pharmaceutical market, which is one of the world&#8217;s fastest-growing. The Healthcare Solutions business, which is now a part of Abbott Labs’ Established Products Division, grew 23% in fiscal 2010 and has a presence in several therapeutic areas including antibiotics, respiratory, cardiovascular, pain and neuroscience. The Established Products Division focuses on branded generics especially in emerging markets. Abbott Labs estimates that the Indian pharma market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/10/abt-abbott-labs-announces-aquisition-of-indian-company-piramal-healthcare/50974/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

